My watch list
my.bionity.com  
Login  

366 Current news from israel

rss
matching the following criteria

Recipharm acquires OnTarget Chemistry and extends its offering into preclinical development services

18-Jun-2015

Recipharm announces that it has completeted the acquisition of OnTarget Chemistry in Uppsala, Sweden. OnTarget Chemistry is a fast growing CRO company with a turnover in 2014 of close to SEK 29 million that is specialized in medicinal chemistry offering synthesis and analytical services which ...

more

Recipharm wins SwedenBIO Award

09-Jun-2015

The winner of the ninth annual SwedenBIO Award was announced on 4th June. This year Recipharm AB was honoured for its efforts and contribution to Sweden life science during the past year.The citation reads: "Recipharm has purposefully and with great skill built a solid organisation with a ...

more

Recipharm appoints Chief Strategy Officer

03-Jun-2015

Recipharm announced that it has appointed Jean-François Hilaire to the new position of Chief Strategy Officer to join Recipharm’s Group Management Team.Jean-François Hilaire is a pharmacist and graduated from the university of Bordeaux and alumni of the CEDEP General Manager Program (campus ...

more

"Hidden" fragrance compound can cause contact allergy

01-Jun-2015

Linalyl acetate, a fragrance chemical that is one of the main constituents of the essential oil of lavender, is not on the list of allergenic compounds pursuant to the EU Cosmetics Directive. Thus, it does not need to be declared on cosmetic products sold within the EU. Recent studies at the ...

more

Are antidepressants more effective than usually assumed?

29-May-2015

Many have recently questioned the efficacy of the most common antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs). The conclusion that these drugs are ineffective is however partly based on a misinterpretation of the outcome of the clinical trials once conducted to ...

more

Recipharm makes strategic investment in Synthonics

16-Apr-2015

Recipharm announced that it has made an equity investment in Synthonics Inc and purchased $2.0 million of preferred stock in the company.A further $2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016. In ...

more

Pharmalink announces positive results in Phase 2b trial of Nefecon

16-Apr-2015

Pharmalink AB announced that the NEFIGAN Trial of Nefecon® for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint. The NEFIGAN Trial is a Phase 2b randomized ...

more

Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe

25-Feb-2015

Infant Bacterial Therapeutics (IBT), subsidiary of BioGaia, is in the early stages of developing a drug to prevent necrotizing enterocolitis (NEC) which is a rare and fatal disease that affects premature infants. IBT has now obtained the Orphan Drug Designation for the prevention of NEC in ...

more

Amyloid formation may link Alzheimer disease and type 2 diabetes

18-Feb-2015

The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D). However, little is known about whether different forms of amyloid proteins interact or how ...

more

Xiapex approved by the EU Commission for the treatment of Peyronie's disease

03-Feb-2015

Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the EU Commission has approved Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Peyronie's ...

more

Page 1 From 37
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE